 Denali Therapeutics NASDAQ:DNLI was downgraded by investment analysts at ValuEngine from a strong-buy rating to a buy rating in a note issued to investors on Friday, ValuEngine reports. Several other research firms also recently issued reports on DNLI. Cantor Fitzgerald restated a neutral rating on shares of Denali Therapeutics in a report on Wednesday, March ... 